Mad Money's Jim Cramer reflects on CNBC's evolution over the past 25 years.» Read More
The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."
A quarter-point cut wasn't enough, he says. So what happens now?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
I'm back at Merck HQ in central Jersey for the annual analyst meeting. And I must say that the reception--so far, at least--is much more hospitable and helpful than last year wen things were tense and got a little ugly. A new pr team is in place.
The Austrian running the world's largest food group talks about trust and the need to delegate in order for an organisation of Nestle's complexity to succeed. Peter Brabeck also hits back at critics of his decision to take the dual mandate of Chairman and CEO, whilst rebuffing journalists who write he's chosen the wrong candidate to succeed him as CEO.
Dow Jones, publisher of the Wall Street Journal, said Thursday that Chief Executive Richard Zannino will leave the company once its acquisition by News Corp is completed.
My inbox is flooded this morning with research notes from analysts in the wake of yesterday's FDA panel meeting on Genentech's Avastin for breast cancer. The advisory committee voted 5-4 against recommending approval of the drug for that use. The FDA usually follows the advice of its outside panels of experts, but in close votes like this one it's not unheard of for the agency to go the other way.
Regular blog readers are well aware of my relentless pursuit of big CEO interviews. So, I wanted to give the backstory to a surprising CEO cancellation of a previously scheduled and confirmed interview today by Bristol-Myers Squibb. A few weeks ago, my producer Ruth and I got tentative confirmation from a Bristol spokesman that the relatively new CEO Jim Cornelius would finally do his first TV interview since taking over the company last year.
China and online advertisers will be the saviors of the advertising industry, according to Sir Martin Sorrell, CEO of advertising giant WPP.
I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.
C-suite confidence is at its lowest level since May of 2003, according to a new survey by Chief Executive Magazine.
Merrill Lynch's new Chief Executive John Thain has received about $2.6 million in restricted stock and nearly 43,000 options to replace shares he forfeited by leaving NYSE Euronext, according to U.S. regulatory filings.
Josef Ackermann, Chief Executive of Deutsche Bank, has turned down an approach from Citigroup about taking the CEO job vacated last month by Charles Prince, the Financial Times reported.
Shares of Dow component Merck are trading lower in the very early going this morning after the country's second-biggest drug company didn't blow people away with its 2008 financial guidance. Merck puts out its new forecast a week ahead of its annual analyst meeting, so it can focus more on its drug development pipeline at the event.
One viewer thinks so. But Cramer won't apologize for being outraged. Also, clearing up the difference between portfolio cash and savings account cash.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Merrill Lynch named NYSE Euronext Chief Financial Officer Nelson Chai as the investment bank's new CFO, replacing Jeffrey Edwards, effective Dec. 10.
You heard me rant here on this blog about Lululemon failing to answer questions about its Vitasea line and whether or not it truly contains seaweed. They were late in issuing a press release and defending their products but finally, in his first public comments, CEO Bob Meers joined us live on CNBC to defend the athletic wear company.
Liquidity is up. Overhead is down. That's the good news at Countrywide Financial, according to Chairman and Chief Executive Angelo Mozilo. But in an exclusive interview with CNBC, Mozilo declined to say that the corner has been turned in the housing and credit markets.
Marsh & McLennan said Monday that Daniel Glaser will become chairman and chief executive of Marsh Inc, the insurance brokerage's main operating subsidiary, effective Dec. 10.
Motorola, which has been fending off criticism from shareholder Carl Icahn, has named Greg Brown as its chief executive, replacing Ed Zander, who will remain chairman until the company's annual meeting in May.
Senator Herb Kohl (D-Wisconsin), the Chairman of the Senate's Special Committee on Aging, has made public a copy of a letter he recently sent to Genentech's President of Product Development, Dr. Susan Desmond-Hellmann--a frequent guest on CNBC--regarding the company's new policy on the use of the eye drug Lucentis.